FDA approves teclistamab-cqyv. for relapsed or refractory multiple myeloma [ https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma

FDA grants accelerated approval to. elranatamab-bcmm for multiple myeloma [ https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma

FDA grants accelerated approval to. talquetamab-tgvs for relapsed or refractory multiple myeloma [ https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma

Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood cancer J. 2020;10(9):94.

Article  PubMed  Google Scholar 

Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor–dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–38.

Article  CAS  PubMed  Google Scholar 

Moreau P, Garfall AL, van de Donk NW, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, et al. Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma. Blood Adv. 2023;7(6):1056–64.

Article  CAS  PubMed  Google Scholar 

Martin TG, Mateos MV, Nooka A, Banerjee A, Kobos R, Pei L et al. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma. Cancer. 2023.

Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NW, Rodríguez-Otero P, et al. Talquetamab, a T-Cell–redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232–44.

Article  CAS  PubMed  Google Scholar 

Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259–67.

Article  CAS  PubMed  Google Scholar 

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–38.

Article  CAS  PubMed  Google Scholar 

Kauer J, Hörner S, Osburg L, Müller S, Märklin M, Heitmann JS et al. Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies. J Immunother Cancer. 2020;8(1).

Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood J Am Soc Hematol. 2008;112(10):3959–64.

CAS  Google Scholar 

Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplantation Cell Therapy. 2023.

Jatiani SS, Aleman A, Madduri D, Chari A, Cho HJ, Richard S, et al. Myeloma CAR-T CRS management with IL-1R antagonist anakinra. Clin Lymphoma Myeloma Leuk. 2020;20(9):632–6. e1.

Article  PubMed  Google Scholar 

Trudel S, Bahlis NJ, Spencer A, Kaedbey R, Rodriguez Otero P, Harrison SJ, et al. Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in patients with Relapsed/Refractory multiple myeloma (RRMM) showed a marked reduction in Cytokine Release Syndrome incidence and severity. Blood. 2022;140(Supplement 1):1363–5.

Article  Google Scholar 

Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958–71.

Article  CAS  PubMed  Google Scholar 

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739–48.

Article  CAS  PubMed  Google Scholar 

Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85–96.

Article  CAS  PubMed  Google Scholar 

Gust J, Hay KA, Hanafi L-A, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7(12):1404–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gust J, Finney OC, Li D, Brakke HM, Hicks RM, Futrell RB, et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019;86(1):42–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galli E, Modoni A, Battistini L, Rossi M, Guerrera G, Pansini I, et al. Blood-brain barrier and neuronal damage during icans in patients treated with Anti-CD19 CAR-T cells. Blood. 2023;142:2128.

Article  Google Scholar 

Touzeau C, Schinke C, Minnema M, Van De Donk NW, Rodríguez-Otero P, Mateos M-V, et al. S191: pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (bsab), for relapsed/refractory multiple myeloma (RRMM). Hemasphere. 2023;7:e5955094.

Article  PubMed Central  Google Scholar 

Steinbach M, Julian K, McClune B, Sborov DW. Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. Therapeutic Adv Hematol. 2022;13:20406207221100659.

Article  CAS  Google Scholar 

Rees JH. Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). The EBMT/EHA CAR-T Cell Handbook. 2022:141-5.

Siegler EL, Kenderian SS. Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies. Front Immunol. 2020;11:550628.

Article  Google Scholar 

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Reviews Clin Oncol. 2018;15(1):47–62.

Article  CAS  Google Scholar 

Ludwig H, Terpos E, van de Donk N, Mateos M-V, Moreau P, Dimopoulos M-A, et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255–69.

Article  CAS  PubMed  Google Scholar 

Giavridis T, van der Stegen SJ, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24(6):731–8.

Article  CAS  PubMed  Google Scholar 

Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood Cancer Discovery. 2023;4(6):440–51.

Article  CAS  PubMed  Google Scholar 

Rasche L, Schinke C, Chari A, Lipe BC, Lavi N, Rodríguez-Otero P et al. Analysis of Infections and Parameters of Humoral Immunity in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab Monotherapy in MonumenTAL-1. HemaSphere. 2023;7(S3):e646904e.

Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Liet Hing MN, et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv. 2023;7(19):5898–903.

Article  CAS  PubMed  Google Scholar 

Hammons L, Szabo A, Janardan A, Bhatlapenumarthi V, Annyapu E, Dhakal B, et al. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma. Haematologica. 2024;109(3):906.

Article  CAS  PubMed  Google Scholar 

Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood cancer J. 2023;13(1):116.

Article  PubMed  Google Scholar 

Lancman G, Parsa K, Rodriguez C, Richter J, Cho HJ, Parekh S, et al. Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood. 2022;140(Supplement 1):10073–4.

Article  Google Scholar 

Ceschi A, Noseda R, Palin K, Verhamme K. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front Pharmacol. 2020;11:529822.

Article  Google Scholar 

Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst A-M, Chan YH, et al. Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol. 2022;13:807050.

Article  CAS  PubMed  Google Scholar 

Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood J Am Soc Hematol. 2013;121(26):5154–7.

CAS